Gut-liver Axis Treatment Options
21st Aug, 2019

This post is specifically for health practitioners. Create a free account

Alternatively, view general public info.

Learn more about vital.ly

Gut Liver Axis Enhanced 

 

Evidence is accumulating on the potential clinical benefits of prebiotics, probiotics and synbiotics in treating chronic liver diseases including non-alcoholic fatty liver disease (NAFLD/NASH), alcohol-related liver disease (ALD) and liver cirrhosis (1). Beneficial effects vary widely in individuals due to vast differences in diet, genetic background and gut microbiome composition and there is limited consensus available in the evidence for specific strains/doses for treatment options in gut-liver axis dysfunction (2). However, the underlying mechanisms of gut dysbiosis and gut permeability highlight the importance of ensuring a healthy and diverse microbiome as the goal of any intervention.

 

Treatment Options

Based on an individual’s microbiota composition, personalised treatment would identify the most promising microbiome-altering treatment plan (3).

 

Treatment options in non-alcoholic fatty liver disease (NAFLD/NASH)

Probiotics, prebiotics and synbiotics have been shown to play pivotal roles in the treatment and prevention of NAFLD. However, inconsistent experimental results need rigorous experimental designs investigating type/strain and effective doses in order to verify the therapeutic effects (2,4,5,6).

 

Probiotics

Several meta-analyses show that probiotics significantly reduce the development of NAFLD in adults and children. In particular, the use of probiotics is associated with lower plasma aminotransferase and total cholesterol levels, lower systemic inflammation and improved insulin resistance. Using different regimens for 8 to 30 weeks can produce positive effects (7,8,9,10).

Lactobacillus and Bifidobacterium are frequently used for their beneficial effects on NAFLD. Probiotic therapies may ameliorate insulin resistance by reducing serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), total cholesterol and TNF-α in NAFLD patients (11).

Some of the research highlighting the effectiveness of probiotics in the management of NAFLD/NASH is given below.

  • VSL#3 supplementation (2 sachets twice per day) improved functional liver markers in NAFLD and alcoholic liver cirrhosis (12). VSL#3 is a mixture containing 450 billion bacteria in various strains (Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus bulgaricus)
  • Treatment with bulgaris or S. thermophilus reduced functional liver markers (13)
  • Supplementation with rhamnosus GG resulted in a significant improvement in liver function in obese children with NAFLD (14)
  • Treatment for 4 months with VSL#3 resulted in a significant improvement in the severity of fatty liver and a significant decrease in body mass index of children with NAFLD (15)
  • 12 weeks of supplementation with a multi-strain probiotic (containing Lactobacillus acidophilus ATCC, B3208; Bifidobacterium lactis DSMZ 32269; Bifidobacterium bifidum ATCC SD6576; Lactobacillus rhamnosus DSMZ 21690) reduced the levels of ALT, AST, cholesterol, low-density lipoprotein-C (LDL-C), triglycerides and waist circumference in children with NAFLD (16)
  • Consuming yoghurt containing acidophilus and B. lactis for 8 weeks in adult patients with NAFLD was associated with a significant improvement of transaminases and cholesterolaemia (17)
  • Improvement in cytokine profile, insulin action and hence glycaemic control was demonstrated in NAFLD after 8 weeks of supplementation with a multi-strain probiotic (Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium longum and Streptococcus thermophiles) (18)

 

Prebiotics and Synbiotics

Synbiotic supplementation has a favourable effect on inflammatory factors, liver enzymes and some anthropometric indices , lipid profiles and glucose homeostasis parameters in individuals with NAFLD (19). A systematic review indicated that synbiotic supplements that contained 20 million - 5 billion CFU bacterial strains and 125mg - 10g prebiotic for 8 - 28 weeks is suggested for NAFLD patients (19).

  • Inulin-type fructans such as oligofructose (16g/day) over 8 weeks improved markers of liver function and disease and decreased insulin levels in individuals with NASH (20)
  • A combination of Bifidobacterium longum and fructooligosaccharide (FOS) administered over 24 weeks reduced TNF-α, CRP, aspartate aminotransferase (AST), insulin resistance and lipopolysaccharide (LPS) as well as decreased NASH activity index in individuals with NASH (21)
  • 24-week consumption of synbiotic yoghurt (containing 108 CFU Bifidobacterium animalis/mL and 1.5 g inulin, 300g daily) improved hepatic steatosis and liver enzyme concentrations in individuals with NAFLD (22)
  • Synbiotic supplementation, twice daily over 28 weeks (200 million bacteria of seven strains: Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum and Lactobacillus bulgaricus) with prebiotic (125mg FOS)) improved the main features of NAFLD in NAFLD patients with normal or low BMI (23)

 

Diet

Although diet can significantly alter both the composition and function of the gut microbiota, clinical studies that link dietary interventions with gut microbiota changes for the treatment of NAFLD/NASH are limited (24).

  • A high-energy, high-fat, high-carbohydrate diet and decreased choline intake alters the gut microbiota and is associated with NASH. Correcting dietary habits is typically part of the standard recommendations for NASH treatment (25)
  • A 3-week high carbohydrate low-fat diet with inulin (prebiotic) reduced hepatic lipogenesis and serum triglyceride levels in a small study (26)
  • A fibre-rich diet is associated with greater richness and diversity of the gut microbiota and is positively associated with the presence of Bacteroidetes and Actinobacteria and a reduction in the Firmicutes:Bacteroides ratio (27). Fibre-rich diets also promote a higher concentration of SCFA, especially butyrate, which has a beneficial effect on inflammation. The replacement of fructose, and other simple carbohydrates, with non-digestible carbohydrates, can avoid the consequences of dysbiosis in the gut-liver axis, especially in NASH (25)
  • Excess protein has been linked with potentially damaging effects on the gut microbiota and health (28). A high-protein diet results in reductions in butyrate-producing bacteria which may increase the risk of NASH (25). Generally, high protein intake is accompanied by a reduction in carbohydrate intake. Therefore, it is possible that the impact of the consumption of high-protein diets on the gut microbiota is related not only to the production of toxic substances derived from protein fermentation but also to the reduction of dietary carbohydrate consumption, especially of non-digestible carbohydrates

 

Table 1. Summary of clinical trials of gut microbiota-targeted therapies on NAFLD/NASH. Adapted from (29) CC BY 4.0

Gut-Lung Axis Enhanced Table 1

 

Figure 1. Multiple pathomechanisms involved in development and progression of non-alcoholic fatty liver disease, and proposed stepwise treatment options (46) CC BY-NC 4.0

Gut-Lung Axis Enhanced Fig 1

 

 

Treatment options in alcohol-related liver disease (ALD)

Recent evidence suggests that probiotics have the ability to transform the composition of the intestinal microbiota community, which leads to the reduction of alcohol-induced dysbiosis, intestinal permeability, bacterial translocation, endotoxaemia, and the development of ALD (2,31). While the transformation of intestinal microbiota by probiotics appears to be a promising therapeutic strategy for the treatment of intestinal barrier dysfunction, there is a scarcity of research that studies probiotics in the context of ALD (31).

  • Administration of casei Shirota (6.5 × 109 CFU, three times daily for 4 weeks, with alcohol abstinence) can restore neutrophil phagocytic capacity in alcoholic cirrhosis, possibly by altering IL-10 secretion and toll-like receptor TLR-4  expression (32)
  • Yakult 400, containing casei (with abstinence state) significantly increased serum levels of liver-specific rapid-turnover protein transthyretin and decreased the level of inflammatory markers in liver cirrhosis patients. In addition, alcohol-induced deterioration of gut flora was improved with the increase of protein production induced by probiotic treatment (33)
  • Supplementation with bifidum and L. plantarum 8PA3 for 5 days may restore the bowel flora and improve alcohol-induced liver injury when combined with standard therapy in ALD patients (34)

 

Treatment options in portal hypertension

Modulation of the gut microbiota via the administration of probiotics has shown promising results in haemodynamic changes in portal hypertension (24).

Six weeks of oral VSL#3 probiotic (2 sachets per day) improved the hepatic and systemic haemodynamics in individuals with cirrhosis (35). Similarly, adjunctive VSL#3 use has been shown to improve the response rate to propranolol  therapy and is safe and well tolerated in individuals with cirrhosis (36). 

 

Treament options in liver transplantation

A meta-analysis of 4 controlled studies demonstrates that giving synbiotics one day before or on the day of transplantation reduces the rate of infections after surgery and shortens hospital and ICU stay as well as antibiotic usage (37). Pre liver transplant administration (for a period of 1 – 10 weeks) of a 4-strain probiotic (Lactococcus lactis PB411, Lactobacillus casei PB121, Lactobacillus acidophilus PB111 and Bifidobacterium bifidum PB211) can help to prevent post-operative infections (38).

 

Mechanisms of action

The role of the gut microbiome in liver disease is underscored by gut dysbiosis and gut permeability.

 

Figure 2. Mechanisms by which gut bacteria affect the hallmarks of nonalcoholic fatty liver disease (39) CC BY 4.0

Gut-Lung Axis Enhanced Fig 2

 

Table 2. Microbiota related mechanisms of action in NAFLD/NASH (4,11,25,40,41,42).

Gut-Lung Axis Enhanced Table 2

 

Figure 3. Gut-liver axis components in normal conditions (right part) and in non-alcoholic fatty liver disease (NAFLD) (47CC BY 4.0

Gut-Lung Axis Enhanced Fig 3

 

Table 3. Mechanism of action - other liver conditions (11,24,31,41,43,44,45)

Gut-Lung Axis Enhanced Table 3

 

Figure 4. The effects of chronic alcohol ingestion on the intestinal microbiome during the development of alcoholic liver disease. Adapted from (49) CC BY-NC 3.0

Gut-Lung Axis Enhanced Fig 1

 

Figure 5. Effects of the intestinal microbiota on HCC tumourigenesis (11) CC BY-NC-ND 4.0

Gut-Lung Axis Enhanced Fig 5

Abbreviations: HCC, hepatocellular carcinoma; HFD, high-fat diet; TLR, Toll-like receptor; HSCs, hepatic stellate cells; DCA, deoxycholic acid; SCFA, short-chain fatty acid.

 

Takeaway on the gut-liver axis

  • Studies suggest that microbial factors are driving forces in many different liver diseases and at various stages of liver diseases. The microbiota affects diverse pathophysiological processes such as hepatic steatosis, liver inflammation, fibrosis development and hepatic encephalopathy. Studies have now convincingly established that the microbiota plays a critical role in these diseases (42)
  • Many studies strongly suggest that targeting the gut microbiome through the use of probiotics, prebiotics, synbiotics and possibly faecal microbiota transplantation (FMT), may be an effective treatment for NAFLD and ALD, improving several parameters including insulin resistance, plasma levels of transaminases and degree of lipid infiltration of the liver (41)
  • Large-scale prospective studies are required to determine how the gut microbes and their metabolites are altered in various clinical settings of liver disease, and to determine which microbial strains affect disease phenotype, that is, either acting protective or detrimental (8,11,41,42)
  • There is still no strong evidence indicating which comes first in ALD; increased permeability and then dysbiosis or dysbiosis inducing increased permeability. It is also not known exactly how direct alcohol toxicity contributes to these changes. ALD can be developed without gut microbiota change and all ALD patients do not have same microbiota composition, therefore, further clinical trials are needed to elaborate on new therapeutic options and mechanisms (31)
Loading...
References
1Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018 Jan;47(2):192–202.
2Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. J Hepatol. 2017;67(5):1084–103.
3Dubinkina VB, Tyakht AV, Odintsova VY, Yarygin KS, Kovarsky BA, Pavlenko AV, et al. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome. 2017 17;5(1):141.
4Han R, Ma J, Li H. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. Front Med. 2018 Dec;12(6):645–57.
5Panasevich MR, Peppler WT, Oerther DB, Wright DC, Rector RS. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. Physiol Genomics. 2017 Aug 1;49(8):385–99.
6Tarantino G, Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol. 2015;10(5):889–902.
7Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. Hepatol Res. 2016 Nov;46(12):1226–33.
8Lavekar A, Raje D, Manohar T, Lavekar A. Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. Euroasian J Hepatogastroenterol. 2017;7(2):130–7.
9Ma Y-Y, Li L, Yu C-H, Shen Z, Chen L-H, Li Y-M. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013 Oct 28;19(40):6911–8.
10Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. Int J Mol Sci. 2016 Jun 13;17(6).
11Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Res. 2018 Mar;2(1):43–51.
12Loguercio C, Federico A, Tuccillo C, Terracciano F, D’Auria MV, De Simone C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005 Jul;39(6):540–3.
13Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011 Sep;15(9):1090–5.
14Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011 Jun;52(6):740–3.
15Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014 Jun;39(11):1276–85.
16Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. J Pediatr Gastroenterol Nutr. 2017;64(3):413–7.
17Nabavi SM, Daglia M, Braidy N, Nabavi SF. Natural products, micronutrients, and nutraceuticals for the treatment of depression: A short review. Nutritional Neuroscience. 2017 Mar 16;20(3):180–94.
18Sepideh A, Karim P, Hossein A, Leila R, Hamdollah M, Mohammad E G, et al. Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial. J Am Coll Nutr. 2016;35(6):500–5.
19Hadi A, Mohammadi H, Miraghajani M, Ghaedi E. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. Crit Rev Food Sci Nutr. 2018 Mar 27;1–12.
20Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr. 2005 May;59(5):723–6.
21Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012 Feb;57(2):545–53.
22Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M. Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. J Nutr. 2018 Aug 1;148(8):1276–84.
23Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017 Mar;117(5):662–8.
24Shen T-CD, Pyrsopoulos N, Rustgi VK. Microbiota and the liver. Liver Transpl. 2018;24(4):539–50.
25de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018 Apr;57(3):861–76.
26Letexier D, Diraison F, Beylot M. Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans. Am J Clin Nutr. 2003 Mar 1;77(3):559–64.
27Kim M-S, Hwang S-S, Park E-J, Bae J-W. Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep. 2013 Oct;5(5):765–75.
28Ma N, Tian Y, Wu Y, Ma X. Contributions of the Interaction Between Dietary Protein and Gut Microbiota to Intestinal Health. Curr Protein Pept Sci. 2017;18(8):795–808.
29Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017 Oct 16;9(10).
30Chen Y, Feng R, Yang X, Dai J, Huang M, Ji X, et al. Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: a randomized controlled trial. Am J Clin Nutr. 2019 Jun 1;109(6):1611–9.
31Hong M, Han DH, Hong J, Kim DJ, Suk KT. Are Probiotics Effective in Targeting Alcoholic Liver Diseases? Probiotics Antimicrob Proteins. 2018 Apr 23;
32Stadlbauer V, Mookerjee RP, Hodges S, Wright GAK, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol. 2008 Jun;48(6):945–51.
33Koga H, Tamiya Y, Mitsuyama K, Ishibashi M, Matsumoto S, Imaoka A, et al. Probiotics promote rapid-turnover protein production by restoring gut flora in patients with alcoholic liver cirrhosis. Hepatol Int. 2013 Jun;7(2):767–74.
34Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, et al. Probiotics Restore Bowel Flora and Improve Liver Enzymes in Human Alcohol-Induced Liver Injury: A Pilot Study. Alcohol. 2008 Dec;42(8):675–82.
35Rincón D, Vaquero J, Hernando A, Galindo E, Ripoll C, Puerto M, et al. Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver Int. 2014 Nov;34(10):1504–12.
36Gupta N, Kumar A, Sharma P, Garg V, Sharma BC, Sarin SK. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int. 2013 Sep;33(8):1148–57.
37Sawas T, Al Halabi S, Hernaez R, Carey WD, Cho WK. Patients Receiving Prebiotics and Probiotics Before Liver Transplantation Develop Fewer Infections Than Controls: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2015 Sep;13(9):1567-1574.e3; quiz e143-144.
38Grąt M, Wronka KM, Lewandowski Z, Grąt K, Krasnodębski M, Stypułkowski J, et al. Effects of continuous use of probiotics before liver transplantation: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2017;36(6):1530–9.
39van Best N, Jansen PL, Rensen SS. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation. Hepatol Int. 2015 Jul;9(3):406–15.
40Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016 01;311(6):G1018–36.
41Cassard A-M, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr. 2017;5(4).
42Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65(12):2035–44.
43Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, et al. Modulation of the Fecal Bile Acid Profile by Gut Microbiota in Cirrhosis. J Hepatol. 2013 May;58(5):949–55.
44Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014 Sep;513(7516):59–64.
45Ridlon JM, Kang D-J, Hylemon PB, Bajaj JS. Gut microbiota, cirrhosis and alcohol regulate bile acid metabolism in the gut. Dig Dis. 2015;33(3):338–45.
46Clemente MG, Mandato C, Poeta M, Vajro P. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol. 2016 Sep 28;22(36):8078–93.
47Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children (Basel). 2017 Aug 2;4(8).
48Zhou Z, Zhong W. Targeting the gut barrier for the treatment of alcoholic liver disease. Liver Res. 2017 Dec;1(4):197–207.
49Chen P, Schnabl B. Host-microbiome interactions in alcoholic liver disease. Gut Liver. 2014 May;8(3):237–41.